Renal failure in a depressed adolescent on escitalopram.

405 ESCITALOPRAM (LEXAPRO) is the most recent selective serotonin reuptake inhibitor (SSRI) approved by the United States Food and Drug Administration (FDA) in 2002 for treatment of adults with major depressive disorder, social anxiety disorder, and generalized anxiety disorder. To date, it has not been approved for use in children or adolescents, as data regarding its safety and efficacy in youths is insufficient. However, it is often prescribed off label in this population for similar indications. This report describes a 17-year-old girl with a history of major depressive disorder and congenital deformity of the upper limbs who developed allergic interstitial nephritis and acute renal failure during a course of treatment with escitalopram.